<<<<With only a year of cash, how can you wait - 9 months from now could be MUCH worse.>>>
Exactly, RPRX is in good shape if the FDA decides they don't need libido studies to obtain an approval for Androxal, however, at what price would RPRX do another financing if QOL's are needed?
The share price is going to suffer as investors concentrate on the finances rather then the pipeline's potential.